Molecular basis of macrolide-lincosamide-streptogramin (MLS) resistance in Finegoldia magna clinical isolates.
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ pharmacology
Bacterial Proteins
/ genetics
DNA, Bacterial
/ genetics
Drug Resistance, Multiple, Bacterial
/ genetics
Female
Firmicutes
/ drug effects
Gram-Positive Bacterial Infections
/ diagnosis
Humans
Lincosamides
/ pharmacology
Macrolides
/ pharmacology
Male
Methyltransferases
/ genetics
Middle Aged
RNA, Ribosomal, 23S
/ genetics
Streptogramins
/ pharmacology
Young Adult
F. magna
GPAC
MLS
anaerobes
clindamycin
erm(A)
erm(B)
Journal
Anaerobe
ISSN: 1095-8274
Titre abrégé: Anaerobe
Pays: England
ID NLM: 9505216
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
03
04
2020
revised:
25
05
2020
accepted:
01
06
2020
pubmed:
13
6
2020
medline:
9
6
2021
entrez:
13
6
2020
Statut:
ppublish
Résumé
Of 69 clinical isolates of Finegoldia magna tested, 36% presented high-level MICs of erythromycin (>256 μg/ml), harboring erm(A) (n = 20) or erm(B) (n=5). Of nine isolates exhibiting an inducible resistance phenotype to macrolides-lincosamides-streptogramins B, four (44%) were susceptible with a potential risk of treatment failure due to emergence of resistant mutants.
Identifiants
pubmed: 32531434
pii: S1075-9964(20)30076-7
doi: 10.1016/j.anaerobe.2020.102220
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
DNA, Bacterial
0
Lincosamides
0
Macrolides
0
RNA, Ribosomal, 23S
0
Streptogramins
0
Methyltransferases
EC 2.1.1.-
rRNA (adenosine-O-2'-)methyltransferase
EC 2.1.1.230
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102220Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.